The most common neuroendocrine tumor of the pancreas is?

Correct Answer: B. Insulinoma

Insulinoma is the most common functional neuroendocrine tumor (NET) of the pancreas, accounting for 70–75% of all pancreatic NETs in most series. The discriminating fact is that insulinomas arise from pancreatic beta cells and present with Whipple's triad: symptomatic hypoglycemia (fasting glucose <55 mg/dL), documented low blood glucose during symptoms, and relief with glucose administration. Most insulinomas (90%) are benign, solitary, and <2 cm in size; only 10% are malignant. They occur sporadically or as part of MEN-1 syndrome (25% of cases in Indian populations with familial clustering). Diagnosis relies on demonstrating inappropriately elevated insulin levels during hypoglycemia (fasting insulin >3 mIU/L when glucose <55 mg/dL) and a positive 72-hour supervised fast test. Localization uses CT/MRI, endoscopic ultrasound (EUS), or intraoperative ultrasound. Treatment is surgical resection, which is curative in >90% of benign cases. The high prevalence and benign nature make insulinoma the most commonly encountered pancreatic NET in clinical practice across Indian teaching hospitals.

Why the other options are wrong

A. VIPoma — VIPomas (vasoactive intestinal peptide-secreting tumors) are rare, accounting for <1% of pancreatic NETs. They present with severe secretory diarrhea (>1 L/day), hypokalemia, and achlorhydria (WDHA syndrome). While clinically dramatic, their rarity makes them far less common than insulinoma. NBE may trap students who remember VIPoma's striking presentation and confuse frequency with clinical impact. C. Gastrinoma — Gastrinomas (gastrin-secreting tumors) are the second most common functional pancreatic NET (~20% of cases), but still significantly less frequent than insulinoma. They cause Zollinger–Ellison syndrome with severe peptic ulcer disease and diarrhea. However, 60–70% are malignant and often extrapancreatic (gastrinoma triangle). The lower overall incidence and higher malignancy rate distinguish them from insulinoma. D. Somatostatinoma — Somatostatinomas are the rarest functional pancreatic NET, accounting for <1% of cases. They present with diabetes, steatorrhea, and achlorhydria due to somatostatin's inhibitory effects on multiple hormones. Their extreme rarity and nonspecific presentation make them a classic 'zebra' diagnosis. NBE may include this to test knowledge of relative frequencies among NETs.

High-Yield Facts

Mnemonics

PNET Frequency (Indian teaching hospitals) Insulinoma (70–75%) > Gastrinoma (20%) > VIPoma (<1%) > Somatostatinoma (<1%). Remember: I-G-V-S in descending order of frequency. Insulinoma Diagnosis: The 72-Hour Fast Fasting glucose <55 mg/dL + Insulin >3 mIU/L + C-peptide elevated (not suppressed) = FIC rule. Proves endogenous insulin secretion, not exogenous injection.

NBE Trap

NBE may pair gastrinoma's dramatic Zollinger–Ellison syndrome presentation with the question to lure students into choosing the most clinically severe NET rather than the most common one. Similarly, VIPoma's striking secretory diarrhea can distract from the epidemiological reality that insulinoma dominates pancreatic NET practice.

Clinical Pearl

In Indian practice, a patient presenting with recurrent fasting hypoglycemia and confusion is insulinoma until proven otherwise—the 72-hour supervised fast remains the gold standard even in resource-limited settings. Early recognition prevents misdiagnosis as psychiatric illness or seizure disorder, which delays definitive surgical cure.

_Reference: Robbins Ch. 20 (Pancreatic Neuroendocrine Tumors); Bailey & Love Ch. 62 (Pancreatic Surgery); Harrison Ch. 379 (Neuroendocrine Tumors)_